Description: Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is headquartered in New York, New York.
Home Page: www.ymabs.com
YMAB Technical Analysis
230 Park Avenue
New York,
NY
10169
United States
Phone:
646 885 8505
Officers
| Name | Title |
|---|---|
| Mr. Thomas Gad | Founder, Interim CEO, Pres, Head of Bus. Devel. & Strategy and Director |
| Mr. Bo Kruse | Exec. VP, Sec., Treasurer & CFO |
| Dr. Steen Lisby M.D., M.Sc. | Sr. VP & Chief Scientific Officer |
| Dr. Vignesh Rajah M.B.A., MBBS | Sr. VP & Chief Medical Officer |
| Mr. Joris Wiel Jan Wilms | Sr. VP & COO |
| Dr. Torben Lund-Hansen M.Sc., Ph.D. | Sr. VP & Head of Technical Operations |
| Ms. Sue Smith | Sr. VP & Chief Commercial Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 119.0476 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.056 |
| Price-to-Sales TTM: | 5.2098 |
| IPO Date: | 2018-09-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 148 |